Oral etoposide in oncology: an evolving role

Area of Science:

• Oncology
• Pharmacology

Background:

• Etoposide has been evaluated in clinical trials for over 20 years.
• Both oral and intravenous etoposide formulations have been utilized.
• The oral route has demonstrated convenience, safety, and efficacy in treating cancers like small cell lung cancer and lymphomas.

Purpose of the Study:

• To review the established clinical trial data for etoposide.
• To highlight the renewed interest in oral etoposide, particularly for elderly patients and extended dosing regimens.
• To introduce ongoing investigations into the value of protracted oral etoposide dosing across diverse diseases.

Main Methods:

• Review of existing clinical trial data.
• Analysis of safety and efficacy profiles for oral etoposide.
• Identification of current research trends and emerging applications.

Main Results:

• Oral etoposide has a proven track record of convenience, safety, and effectiveness.
• There is a resurgence in interest for oral etoposide, especially in specific patient populations and dosing strategies.
• New investigations are actively assessing the benefits of prolonged oral etoposide administration.

Conclusions:

• Oral etoposide remains a valuable therapeutic option with a well-documented history of success.
• The drug's utility is being re-evaluated for novel applications, including in the elderly and with extended dosing.
• Further research is warranted to fully elucidate the potential of protracted oral etoposide regimens in various oncological settings.